Innovative Cell-Based Immunization Technique Developed

German researchers have developed a novel system aimed at enhancing immunization studies. Their innovative method, designed to display epitopes in mammal cells, holds significant promise for expediting the production of antibodies crucial for vaccine development.

The critical initial step in vaccine creation involves promoting blood cells to generate antibodies against specific viral proteins. However, this process poses challenges, as the effectiveness of vaccines depends on how antigens, the virus components administered for testing, are designed and delivered.

A key aspect of virus research revolves around expressing and purifying antigens for vaccination. While animals immunized with prepared antigens produce antibodies against them, scientists must isolate these antigens to create targeted vaccines. Isolating antigens, particularly in the case of lab-produced ones with rapidly mutating viruses, is time-consuming and can take several weeks.

The newly devised method, described in a Biology Methods & Protocols paper, addresses this challenge by inducing specific immune responses. The team accomplished this by fusing antigen proteins into a tetraspanin-derived anchor membrane-bound protein, creating fusion proteins prominently displayed on the surface of human cells. This surface presentation, facilitated by a carrier protein, triggers antibody production against relevant antigens. Notably, these antigens mimic the conformation and modifications of proteins in the virus, as they are produced by cells similar to those the virus naturally infects.

This innovative display technology presents a potentially more reliable immunization technique. The researchers successfully induced antibodies against various proteins, focusing on the receptor-binding domain of SARS-CoV-2. Importantly, the anchor protein enables targeted disease-specific immunization without the need for antigen purification, potentially significantly expediting the immunization process.

Corresponding author Daniel Ivanusic, from the Robert Koch Institute, expressed excitement about the technology's potential, especially in inducing neutralizing antibodies against HIV-1. The researchers believe this breakthrough marks just the beginning of a compelling new era in immunization techniques, offering a faster and more efficient approach to vaccine development.